From Cheap Assembly to Deep Manufacturing (Who the Budget Really Backs)
The budget quietly shifts India from assembling products to owning technology, components, and intellectual property.
For years, India assembled phones, exported generic drugs, and imported key parts.
Budget 2026–27 signals a break from that pattern.
Instead of rewarding volume, it rewards complexity.
Biopharma SHAKTI (₹10,000 crore): pushing India into biologics and biosimilars.
Electronics components outlay raised to ₹40,000 crore: focus shifts from phones to chips, lenses, PCBs.
Semiconductors & AI infrastructure: capital-heavy, long-gestation bets.
These sectors don’t employ the most people immediately—but they build pricing power, exports, and strategic independence.
That’s why labour-light but capital-deep companies gain priority.
NIFTY 500 Stocks Benefiting:
Biocon